Abliva

Abliva is a clinical-stage biotech company dedicated to addressing the high unmet medical need in primary mitochondrial diseases, a rare and severe orphan condition affecting an estimated 1 in 5,000 people. The company leverages in-house R&D capabilities to build a portfolio of small molecule projects with mechanisms of action suitable for a range of mitochondrial disorders, with programs spanning from early discovery to clinical phases. Its acquisition by Pharming Group in mid-2025 provides a strategic parent with resources and commercial expertise in rare diseases, potentially accelerating the development and future commercialization of Abliva's pipeline.

In-house R&D platform for discovering small molecules with mechanisms of action targeting mitochondrial function, suitable for a wide range of primary mitochondrial diseases.

Mitochondrial medicine is an area of increasing focus, but the landscape for primary mitochondrial disease remains relatively nascent with few late-stage clinical candidates. Competition may come from other small biotechs and, increasingly, larger pharmaceutical companies exploring metabolic and rare genetic disorders. Abliva's specialized focus and Pharming's backing provide a competitive edge.